eBook - ePub
Autologous Stem Cell Transplantation
Biological and Clinical Results in Malignancies
This is a test
- 600 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Book details
Book preview
Table of contents
Citations
About This Book
This textbook integrates basic research and clinical aspects underlying the most recent results in those malignant diseases where progress is most effective.
Recent evidence shows that higher doses are better in inducing higher cure rates in hematological neoplasias, although myeloblation related to dose intensity can be a limiting factor. The toxicity can now be controlled with autologous marrow and peripheral blood progenitor cell transplantation, used with or without growth factors. The combination of high dose chemoradiotherapy followed by re-infusion of autologous stem cells constitute a dramatic advance in the treatment of refactory and relapse hematological neoplasias.
Frequently asked questions
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Both plans give you full access to the library and all of Perlegoâs features. The only differences are the price and subscription period: With the annual plan youâll save around 30% compared to 12 months on the monthly plan.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weâve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes, you can access Autologous Stem Cell Transplantation by Angelo Carella in PDF and/or ePUB format, as well as other popular books in Medicine & Surgery & Surgical Medicine. We have over one million books available in our catalogue for you to explore.
Information
1 AUTOTRANSPLANT ACTIVITY 1989â1994
Autologous Blood & Marrow Transplant Registry â North America, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA; Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc., Los Angeles, USA; and the University of Nebraska Medical Center, Omaha, USA
Auto transplants are increasingly used to treat cancer. In 1989 the National Institutes of Health of the United States began support of the Autologous Blood & Marrow Transplant Registry (ABMTR) to study outcomes of autotransplants. The ABMTR is a voluntary scientific organization of more than 130 auto transplant centers in the US, Canada, South America, Russia, Cuba and Austria. Distribution of centers and registered cases is indicated in Table 1.
The ABMTR registers all consecutive autotransplants at participating centers. More detailed reporting is requested in specific diseases. Presently these are breast cancer, lymphomas and acute myelogenous and lymphoblastic leukemias (AML, ALL). Detailed reporting will begin soon for multiple myeloma.
The more than 14,000 autotransplants done between January 1989 and June 1994 at participating centers are summarized in Figure 1 and Table 2. Most autotransplants (N = 5845) were for lymphomas (non-Hodgkin, N = 3708; Hodgkin, N = 2137), breast cancer (N = 4004), acute myelogenous leukemia (N = 1433) and multiple myeloma (N = 610). A detailed description is presented in Table 2. We estimate that these include about 50% of all autotransplants done in North America during this time period.
Table 3 describes the more than 3000 cases reported in detail to the ABMTR during this interval including breast cancer (N = 1346), lymphomas (N = 1134; non-Hodgkin, N = 739; Hodgkin, N = 395) and leukemia (N = 780; AML, N = 600; ALL, N = 180).
Geographic Area | Registering Teams | Registered Patients |
United States | 117 | 13531 (88%) |
Canada | 18 | 1312 (9%) |
South America | 4 | 322 (2%) |
Other | 3 | 109 (1%) |
TOTAL | 142 | 15274 |
Acute myelogenous leukemia 600 Acute lymphoblastic leukemia 180 Non-Hodgkin lymphoma 739 Hodgkin disease 395 Breast cancer 1346 TOTAL 3260 aComprehensive clinical data available for all cases.
These data indicate increasing use of autotransplants in cancer. Future ABMTR studies will consider variables associated with transplant outcome, compare results of auto- and allotransplants and compare autotransplant outcome with other therapies.
Supported by Public Health Service Grant No. PO1-CA-40053 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute of the U.S. Department of Health and Human Services; the U.S. Army Medical Research and Development Command; and by grants from Amgen Inc.; Astra Pharmaceutical Products; Baxter Healthcare Corporation; Bristol-Myers Oncology; Caremark, Inc.; CellPro, Inc.; Center for Advanced Studies in Leukemia; COBE BCT, Inc.; Glaxo Pharmaceutical; Hewlett-Packard Company; Immunex Corporation; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Lederle Laboratories; Marion Merrell Dow Inc.; Milstein Family Foundation; Milwaukee Foundation/Elsa Schoeneich Research Fund; Ortho Biotech, Inc.; Pharmacia; Quadra Logic Technologies; Roerig/Pfizer Pharmaceuticals; Sandoz Oncology; StemCell Technologies; SyStemix; and Upjohn Company.
Table of contents
- Cover
- Half Title
- Title Page
- Copyright Page
- Table of Contents
- Introduction to the Series
- Preface
- Foreword
- 1 Autotransplant Activity 1989â1994
- 2 Purification and Evaluation of Hematopoietic Stem Cells for Transplantation
- 3 Cytokine Regulation of Primitive Progenitors in Culture
- 4 Isolation of both Normal and Leukemic Cells within the Hematopoietic Stem Cell Compartment of Chronic Myelogenous Leukemia Mobilized Peripheral Blood
- 5 Expansion and Clinical Use of Hematopoietic Progenitor Cells in Human Marrow and Peripheral Blood
- 6 Theoretical Basis for Autografting
- 7 Pattern of Reconstitution and Relapse following Autologous Bone Marrow Transplantation for Chronic Myelogenous Leukemia
- 8 Harnessing Immune Control of Leukemia in Autografting
- 9 Pharmacology of High-Dose Therapy with Bone Marrow Transplantation
- 10 The Detection of Minimal Residual Disease in Acute Leukemia
- 11 Marrow Contamination: Detection and Significance
- 12 Marrow Contamination: Pharmacological Treatment
- 13 Marrow Contamination: Immunological Treatment
- 14 Hemopoietic Growth Factors and Autografting
- 15 Autologous Graft-versus-Host Disease
- 16 Approaches to Improving the Results of Total Body Irradiation in Marrow Transplantation
- 17 Pretransplant Regimens without Total Body Irradiation (TBI)
- 18 New Pre-transplant Regimens
- 19 How does Autologous Hemopoietic Cell Transplantation Cure Acute Myeloid Leukemia?
- 20 Treatment of Acute Lymphoblastic Leukemia (ALL) in Adults: Problems and Pitfalls
- 21 Autologous Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Children
- 22 Autologous Bone Marrow Transplantation for Acute Lymphoblastic Leukemia in Adults
- 23 Treatment of Acute Myloid Leukemia: State of the Art
- 24 The Present Status of Autologous Bone Marrow Transplantation in Acute Myeloid Leukaemia
- 25 Minimal Residual Disease in Leukemia
- 26 Autografting for Chronic Myelogenous Leukemia: Is there a Role?
- 27 Autografting with Cultured Marrow for the Myeloid Leukemias: The Vancouver Experience
- 28 In Vivo Mobilization of Ph1 - Negative Peripheral Blood Progenitor Cells and Autografting in Chronic Myelogenous Leukemia: The Genoa Experience
- 29 How does Autografting Cure Aggressive Malignant Non-Hodgkinâs Lymphoma?
- 30 The Role of Autografting in Low-grade Lymphoma
- 31 Autologous Stem Cell Transplantation in Intermediate and High Grade Lymphoma
- 32 Autografting for Lymphoblastic Lymphoma
- 33 High Dose Therapy (HDT) in Burkittâs Lymphoma
- 34 Autografting for Hodgkinâs Disease
- 35 The Role of Intensive Therapy and Autotransplantation for Hodgkinâs Disease Patients in an Initial Complete or Partial Remission
- 36 Autologous Transplants for Multiple Myeloma
- 37 Autografting in Breast Cancer
- 38 High Dose Chemotherapy with Stem Cell Support for Miscellaneous Solid Tumors
- 39 High-Dose Therapy followed by Bone Marrow Rescue in Pediatric Solid Tumors
- 40 Autografting with Blood Stem Cell in Hematological Neoplasias: Review of Indications
- 41 Umbilical Cord Biology and Transplant
- 42 Immunotherapy by Allogeneic Lymphocytes and Cytokines following Autologous and Allogeneic Bone Marrow Stem Cell Transplantation
- 43 Immune Ablation Followed by Stem Cell Transplantation (Allogeneic) or Support (Autologous) for Severe Autoimmune Diseases Progress, Controversies and Suggested Guidelines
- Index